Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Regulator and the Regulated Part I: A Conversation with FDA's Robert Temple and Amgen's Roger Perlmutter

This article was originally published in RPM Report

Executive Summary

FDA’s dean of drug development Robert Temple and Amgen’s head of research and development Roger Perlmutter sat down for a conversation at the recent FDA/CMS Summit to discuss opportunities and challenges for biopharmaceutical developers in the current regulatory environment.

You may also be interested in...



Many Drug Approval Delays, Denials Could Be Prevented, FDA Study Shows

Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.

If Sponsors Don’t Ask, FDA Can’t Always Deliver: Merck’s Suvorexant Dosing Debacle

Sponsors may need to be more proactive in reaching out to the agency if they want to avoid the kind of dosing confusion currently facing Merck’s insomnia drug suvorexant, FDA indicates.

The Regulator and the Regulated Part II: A Conversation with FDA's Robert Temple and Amgen's Roger Perlmutter

FDA’s dean of drug development Robert Temple and Amgen’s head of research and development Roger Perlmutter sat down to discuss opportunities and challenges for biopharmaceutical developers in the current regulatory environment during The RPM Report’s FDA/CMS Summit for Biopharma Executives. This is part two of that discussion.

Related Content

Topics

UsernamePublicRestriction

Register

PS080790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel